Last reviewed · How we verify
Study of HBI0101 (NXC-201) CAR-T Therapy in Multiple Myeloma and Light-Chain Amyloidosis
A Phase II study of HBI0101 (NXC-201) BCMA-CART in Multiple Myeloma and Light-chain Amyloidosis Patients. The goal of the study is to evaluate the efficacy and safety of HBI0101 CART.
Details
| Lead sponsor | Polina Stepensky |
|---|---|
| Phase | PHASE2 |
| Status | RECRUITING |
| Enrolment | 180 |
| Start date | Sat Mar 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Wed May 15 2030 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Multiple Myeloma, Refractory to Standard Treatment
- Multiple Myeloma, Relapsed
- Light Chain Amyloidosis
Interventions
- HBI0101 CART
Countries
Israel